Golidocitinib for adults with hard-to-treat ITP
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests the drug Golidocitinib (a JAK inhibitor) in adults with primary immune thrombocytopenia (ITP) that has not responded well to standard treatments. The goal is to see if it can safely raise and stabilize platelet counts.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have had primary ITP for more than 3 months.
- Your platelet count has been below 30 on two separate tests at least a week apart.
- Your ITP has come back after treatment or hasn't responded to corticosteroids and at least one other ITP therapy.
- You have had some response to past ITP treatments.
- Your liver, kidney, and blood cell levels are working well enough.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding iguratimod (a medicine that helps control immune system activity) to a low dose of rituximab (a targeted therapy for immune cells) works better than low-dose rituximab alone for people with ITP that has not responded to steroid treatment or that comes back after steroids are stopped.
This study tests an investigational drug called DZD8586 for people with long-term ITP (low platelets) that hasn't improved with standard treatments. The goal is to see if it can safely raise platelet counts and reduce bleeding risk.
This trial tests a combination of upadacitinib (a pill that calms the immune system) and high-dose dexamethasone (a steroid) as the first treatment for adults with newly diagnosed immune thrombocytopenia (ITP). It aims to see if this mix can safely raise platelet counts better than steroids alone.
This trial tests an investigational drug called CID-103 for adults with chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets. It aims to find the right dose and see if it can safely increase platelet counts to reduce bleeding risk.
This trial tests a new antibody drug (anti-CD38) compared to a standard drug (rituximab) for adults with ITP that hasn't responded well to steroids. The goal is to see if the new drug works better at raising platelet counts and reducing bleeding risk.
This trial tests whether adding a new drug (telitacicept) to a standard platelet booster (eltrombopag) works better than eltrombopag alone for adults whose ITP has not responded to steroids.
Hear when a new Immune Thrombocytopenia (ITP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.